Interstitial lung disease and idiopathic inflammatory myopathies: Progress and pitfalls

Current Opinion in Rheumatology

Volumn 22, Issue 6, 2010, Pages 633-638

  Labirua, Ane ^a   Lundberg, Ingrid E ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

dermatomyositis; interstitial lung disease; polymyositis

Indexed keywords

AUTOANTIBODY; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ENZYME ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; STEROID; TACROLIMUS;

ANTISYNTHETASE SYNDROME; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; HUMAN; IDIOPATHIC INFLAMMATORY MYOPATHY; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LUNG DISEASE; LUNG FUNCTION; MYOPATHY; MYOSITIS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL; TREATMENT OUTCOME;

AUTOANTIBODIES; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOPHENOTYPING; LUNG DISEASES, INTERSTITIAL; MYOSITIS;

EID: 77958040966     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32833f1970     Document Type: Review

References (47)

1. Fathi M, Lundberg IE. Interstitial lung disease in polymyositis and dermato-myositis. Curr Opin Rheumatol 2005; 17:701-706.
2. Selva-O'Callaghan A, Labrador-Horrillo M, Muñoz-Gall X, et al. Polymyositis/ dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus 2005; 14:534-542.
3. Chen IJ, Jan Wu YJ, Lin CW, et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 2009; 28:639-646.
4. Fathi M, Vikgren J, Boijsen M, et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008; 59:677-685.
5. Chinoy H, Salway F, Fertig N, et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006; 8:R13.
6. Lundberg IE, Grundtman C. Developments in the scientific and clinical understanding of inflammatory myopathies. Arthritis Res Ther 2008; 10:220.
7. Levine SM, Raben N, Xie D, et al. Novel conformation of histidyl-transfer RNA synthetase in the lung. Arhtritis Rheum 2007; 56:2729-2739.
8. Barbasso S, Englund P, Engstrom M, et al. Sera from anti-Jo-1 positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells. Arthritis Rheum 2009; 60:2524-2530.
9. Lundberg IE, Barbasso S. The type I interferon system in idiopathic inflammatory myopathies. Autoimmunity 2010; 43:239-243. doi: 10.3109/ 08916930903510955.
10. Targoff IN. Autoantibodies and their significance in myositis. Curr Rheumatol Rep 2008; 10:333-340.
11. Marguerie C, Bunn CC, Beynon HLC, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990; 77:1019-1038.
12. Vancsa A, CsípoI, Nemeth J, et al. Chacarteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int 2009; 29:989-994.
13. Mileti LM, StrekME, Niewold TB, et al. Clinical characteristics of patients with anti-Jo-1 antibodies. J Clin Rheumatol 2009; 15:254-255.
14. Dugar M, Cox S, Limaye V, et al. Clinical heterogeneity and prognostic features of South Australian patients with antisynthetase antibodies. Intern Med J 2009. doi: 10.1111/j.1445-5994.2009.02164.x. [Epub ahead of print]
15. Miller WF, Waite KA, Biswas T, Plotz PH. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci \USA 1990; 87:9933-9937.
16. Sato S, Hirakata M, Kuwana M, et al. Clinical characteristics of Japanese patients with anti-PL-7 (antithreonyl-tRNA synthetase) autoantibodies. Clin Exp Rheumatol 2005; 23:609-615. (Pubitemid 41300701)
17. Yamasaki Y, Yamada H, Nozaki T, et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 2006; 54: 2004-2009.
18. Kalluri M, Sahn SA, OddisCV, et al. Clinical profile of anti-PL12 autoantibody: cohort study and review of the literature. Chest 2009; 135:1550-1556.
19. Hervier B, Wallaert B, Hachulla E, et al. Clinical manifestations of antisynthe-tase syndrome positive for antialanyl-tRNA synthetase (anti-PL12) antibodies:a retrospective study of 17 cases. Rheumatology 2010; 49: 972-976. doi:10.1093/rheumatology/kep455.
20. Targoff IN, Arnett FC. Clinical manifestations in patients with antibody to PL-1 2 antigen (alanyl-tRNA synthetase). Am J Med 1990; 88:241-251.
21. Targoff IN, Trieu EP, Plotz PH, Miller FW. Antibodies to glycyl-transfer RNA synthetase in patients with myositis and interstitial lung disease. Arthritis Rheum 1992; 35:821-830.
22. Sato S, Kuwana M, Hirakata M. Clinical characteristics of Japanese patients with anti-OJ (antiisoleucyl-tRNA synthetase) autoantibodies. Rheumatology 2007; 46:842-845. (Pubitemid 47061719)
23. Hirakata M,Suwa A, TakadaT. Clinical and immunological features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum 2007; 56:1295-1303.
24. Hashish YRS, Hashish L, Trieu EP, et al. Identification of autoantibodies to tyrosil-tRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome [abstract]. Arthritis Rheum 2005; 52(Suppl): S312.
25. BetteridgeZ, GunawardenaH, North J, et al. Antisynthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology 2007; 46:1005-1008.
26. Friedman AW, Targoff IN, Arnett FC. Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis. Semin Arthritis Rheum 1996; 26:459-467.
27. Takahashi T, Wada I, Ohtsuka Y, et al. Autoantibody to alanyl-tRNA synthetase in patients with idiopathic pulmonary fibrosis. Respirology 2007; 12: 642-653.
28. Fisher A, Swigris JJ, du Bois RM, et al. Antisynthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med 2009; 103:171 9-1724.
29. Rutjes SA, Vree Egberts WT, Jongen P, et al. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997; 109:32-40.
30. La Corte R, Lo Monaco A, Locaputo A, et al. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 2006; 39:249-253.
31. SatoS, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52:1571-1576.
32. Nakashima R, ImuraY, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology 2010; 49:433-440.
33. Fujikawa K, Kawakami A, Kaji M, et al. Association of distinct clinical subsets with myositis-specific autoantibodies towards anti155/140-kDa polypep tides, anti140-kDa polypeptides, and antiaminoacyl-tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study. Scand J Rheumatol 2009; 38:263-267.
34. Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinicallyamyopathic dermatomyositis. Arthritis Rheum 2009; 60:2193-2200.
35. Ye E, Chen XX, Lu XY, et al. Adult clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol1 2007; 26: 1647-1654.
36. Mukae H, Ishimoto H, Sakamoto N, et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositisand classic dermatomyositis. Chest 2009; 136:1341-1347.
37. Hengstman GJD, van den Hoogen FHJ, van Engelen BGM. Treatment of the inflammatory myopathies: update and practical recommendations. ExpertOpin Pharmacother 2009; 10:1183-1190.
38. Dalakas MC. Immunotherapy of myositis: issues, concerns and future pro-spects. Nat Rev Rheumatol 2010; 6:129-137.
39. Wilkes M, Sereika S, Fertig N, et al. Treatment of antisynthetase associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005; 52:2439-2446.
40. Ando M, Miyazaki E, Yamasue M, etal. Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol 2010; 29:443-445.
41. Guglielmi S, Merz TM, Gugger M, et al. Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus. Eur Respir J 2008; 31:213-217.
42. Hervier B, Masseau A, Mussini JM, etal. Long-term efficacy of mycophenolate mofetil in a case of refractory antisynthetase syndrome. Joint Bone Spine2009; 76:570-576.
43. Suzuki Y, Hayakawa H, MiwaS, etal. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/ dermatomyositis. Lung 2009; 187:201-206.
44. Vandenbroucke E, Grutters JC, Altenburg J, etal. Rituximab in life threateningantisynthetase syndrome. Rheumatol Int 2009; 29:1499-1502.
45. Sem M, Molberg Ø, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. Rheumatology 2009;48:968-971.
46. Kim J, Kim YW, Lee SM, etal. Successful lung transplantation in a patient with dermatomyositis and acute form of interstitial pneumonitis. Clin Exp Rheumatol 2009; 27:168-169.
47. Shoji T, Bando T, Fujinaga T, et al. Living-donor lobar lung transplantation forinterstitial pneumonia associated with dermatomyositis. Transplant Int 2010;23:e.10-e.11. doi: 10.1111/j.1432-2277.2010.01066.x.